Serum reactivity to citrullinated protein/peptide antigens and left ventricular structure and function in the Multi-Ethnic Study of Atherosclerosis (MESA)

• Published in: PloS one Vol. 18; no. 10; p. e0291967
• Main Authors: Hughes-Austin, Jan M, Katz, Ronit, Majka, Darcy S, Criqui, Michael H, Robinson, William H, Firestein, Gary S, Hundley, W Gregory, Ix, Joachim H
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 24.10.2023; Public Library of Science (PLoS)
• Subjects: Aged; Analysis; Antigen-antibody reactions; Arthritis; Arthritis, Rheumatoid; Atherosclerosis; Biology and Life Sciences; Care and treatment; Complications and side effects; Female; Heart Failure; Humans; Hypertension; Immunity; Magnetic Resonance Imaging; Male; Medicine and Health Sciences; Middle Aged; Peptides; Prevention; Proportional Hazards Models; Research and Analysis Methods; Rheumatoid arthritis; Risk factors; Ventricular Function, Left; United States
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0291967

Antibodies to citrullinated protein antigens have been linked to altered left ventricular (LV) structure and function in patients with rheumatoid arthritis (RA). Serum reactivity to several citrullinated protein/peptide antigens has been identified in RA, which are detectable years before RA onset and in individuals who may never develop RA. Among community-living individuals without heart failure (HF) at baseline in the Multi-Ethnic Study of Atherosclerosis (MESA), we investigated associations between serum reactivity to citrullinated protein/peptide antigens, LV mass, LV ejection fraction (LVEF), and incident HF. Among 1232 MESA participants, we measured serum reactivity to 28 different citrullinated proteins/peptides using a multiplex bead-based array. Each antibody was defined as having extremely high reactivity (EHR) if >95th percentile cut-off in MESA. Number of EHR antibody responses to citrullinated protein/peptide antigens were summed for each participant (range 0-28). LV mass(g) and LVEF(%) were measured on cardiac MRI. Associations between EHR antibodies and LV mass and LVEF were evaluated using linear regression. Cox proportional hazards models were used to evaluate associations between EHR antibodies and incident HF during 11 years of follow-up, adjusting for age, gender, race/ethnicity, smoking status, systolic blood pressure, use of anti-hypertensive medications, self-reported arthritis, IL-6, body surface area, and estimated glomerular filtration rate. Mean age was 65±10, 50% were female, 40% were White, 21% were Black, 26% were Hispanic/Latino, and 14% were Chinese. Twenty-seven percent of MESA participants had extremely high reactivity to ≥ 1 citrullinated protein/peptide antigen. In fully adjusted analysis, every additional EHR antibody was significantly associated with 0.1% lower LVEF (95% CI: -0.17%, -0.02%). No association was observed with LV mass (β per additional EHR antibody) = 0.13±0.15 (p = 0.37)). Neither the presence nor number of EHR antibodies was associated with incident HF during follow-up (HR per additional EHR antibody = 1.008 (95% CI: 0.97, 1.05)). Greater number of extremely highly reactive antibodies was associated with lower LVEF, but not with LV mass or incident HF. Thus, serum reactivity to citrullinated protein/peptide antigens was associated with subtle subclinical changes in myocardial contractility, but the significance in relation to clinically apparent HF is uncertain.